Cargando…
我国孤立性浆细胞瘤的患病率调查:基于全国2016年城镇医疗保险数据的测算
OBJECTIVE: The aim of this study is to analyze the distribution features of patients with solitary plasmacytoma and calculate the prevalence of solitary plasmacytoma in China in the year 2016. METHODS: This study was based on China's urban employees' basic medical insurance and the urban r...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378283/ https://www.ncbi.nlm.nih.gov/pubmed/32654456 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.06.003 |
Sumario: | OBJECTIVE: The aim of this study is to analyze the distribution features of patients with solitary plasmacytoma and calculate the prevalence of solitary plasmacytoma in China in the year 2016. METHODS: This study was based on China's urban employees' basic medical insurance and the urban residences' basic medical insurance from 21 provinces from January 1, 2016 to December 31, 2016. Patients with solitary plasmacytoma were identified by disease names and codes. Subgroup analyses were carried out by sex, region, and age. Furthermore, sensitivity analyses were performed to test the robustness of the results. Age-adjusted prevalence was calculated based on the 2010 Chinese census data, the 2013 Revised European Standard Population, the 2010 US population, and the 2011 Australian population. RESULTS: In 2016, the prevalence of solitary plasmacytoma in China was 1.18 per 100 000 population (95%CI, 1.06–1.31), with 1.26 per 100 000 population (95% CI, 1.10–1.43) and 1.10 per 100 000 population (95% CI, 0.93–1.29) for males and females, respectively. The age-adjusted prevalence based on the 2010 Chinese census data was 0.85 per 100 000 population (95% CI, 0.82–0.88). CONCLUSION: This study estimated the prevalence of solitary plasmacytoma in China on the basis of the national urban medical insurance, which can provide clues for the enactment of solitary plasmacytoma-related medical policies and basic studies about solitary plasmacytoma. |
---|